🇺🇸 FDA
Patent

US 9730954

miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers

granted A61KA61K31/7105A61K31/713

Quick answer

US patent 9730954 (miRNAs as novel therapeutic adjuvants and biomarkers for the prognosis and treatment of drug resistant breast cancers) held by The Board of Regents of the University of Texas System expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/7105, A61K31/713, A61K45/06, A61P